GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Buyback Yield %

MaxCyte (LSE:MXCT) Buyback Yield % : 0.00 (As of May. 28, 2024)


View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

MaxCyte's current buyback yield was 0.00%.


MaxCyte Buyback Yield % Historical Data

The historical data trend for MaxCyte's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Buyback Yield % Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.11 -7.02 -23.23 - -0.06

MaxCyte Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MaxCyte's Buyback Yield %

For the Medical Devices subindustry, MaxCyte's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte's Buyback Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where MaxCyte's Buyback Yield % falls into.



MaxCyte Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

MaxCyte's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.213) / 366.46605
=-0.06%

MaxCyte's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 357.587125
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


MaxCyte Buyback Yield % Related Terms

Thank you for viewing the detailed overview of MaxCyte's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte (LSE:MXCT) Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.